Tenofovir

Generic Name: Tenofovir

Brand Names: Vemlidy, Tenofovir disoproxil Zentiva

Drug Type: Small Molecule

Chemical Formula: C_₉H_₁₄N_₅O_₄P

CAS Number: 147127-20-6

Unique Ingredient Identifier: W4HFE001U5

Background: Tenofovir is an acyclic nucleotide diester analog of adenosine monophosphate. In the most strict sense and due to the fact that it presents a phosphate group bound to the nitrogenous base, it is determined as an actual nucleotide analog. The antiviral activities of tenofovir were first reported in 1993 and this agent was commercially available since 2008 in ...

Indication: Tenofovir has been shown to be effective against HIV, herpes simplex virus-2, and hepatitis B virus.

To know more about the specific product indications, please visit the information in the orally available forms of tenofovir, tenofovir alafenamide and tenofovir disoproxil.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Differences Between Stavudine and Tenofovir Each Combined With Lamivudine and Efavirenz in SA HIV-infected Patients

Phase 4

Terminated

Conditions: Mitochondrial Toxicity
Metabolic Complications

Interventions: Drug: Tenofovir
Drug: Stavudine

First Posted Date: 2012-05-18

Last Posted Date: 2012-05-18

Lead Sponsor: University of Witwatersrand, South Africa

Target Recruit Count: 60

Registration Number: NCT01601899

Locations: 🇿🇦
Themba Lethu Clinic, Helen Joseph Hospital, Auckland Park, Johannesburg, Gauteng, South Africa

Efficacy of Telbivudine With or Without add-on Tenofovir According to Roadmap Strategy Compare With Entecavir

Phase 4

Conditions: Chronic Hepatitis B

Interventions: Drug: Telbivudine
Drug: Entecavir
Drug: Tenofovir

First Posted Date: 2012-05-01

Last Posted Date: 2012-05-02

Lead Sponsor: Pusan National University Yangsan Hospital

Target Recruit Count: 104

Registration Number: NCT01588912

Locations: 🇰🇷
Byung Chul Yoon, Busan, Korea, Republic of
🇰🇷
Eun Uk Jung, Busan, Korea, Republic of
🇰🇷
Hyun Young Woo, Busan, Korea, Republic of

and more 7 locations

Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients

Phase 1

Completed

Conditions: Hepatitis C, Chronic

Interventions: Drug: tenofovir
Drug: tolbutamide
Drug: BI 207127
Drug: midazolam
Drug: caffeine
Drug: BI 201335
Drug: pegylated interferon
Drug: ribavirin

First Posted Date: 2012-02-03

Last Posted Date: 2016-06-10

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 72

Registration Number: NCT01525628

Locations: 🇺🇸
1241.27.0006 Boehringer Ingelheim Investigational Site, La Mesa, California, United States
🇺🇸
1241.27.0003 Boehringer Ingelheim Investigational Site, Philadelphia, Pennsylvania, United States
🇺🇸
1241.27.0004 Boehringer Ingelheim Investigational Site, Marlton, New Jersey, United States

and more 13 locations

Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive

Phase 2

Terminated

Conditions: HIV-1 Infection

Interventions: Drug: BMS-986001
Drug: Placebo matching with BMS-986001
Drug: Lamivudine
Drug: Efavirenz
Drug: Tenofovir

First Posted Date: 2011-12-09

Last Posted Date: 2016-04-15

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 297

Registration Number: NCT01489046

Locations: 🇺🇸
Orlando Immunology Center, Orlando, Florida, United States
🇺🇸
Jacobi Medical Center, Bronx, New York, United States
🇹🇭
Local Institution, Nontaburi, Thailand

and more 12 locations

Combination Therapy of Pegylated Interferon Alfa-2a and Tenofovir Versus Tenofovir Monotherapy in Chronic Hepatitis B

Phase 3

Completed

Conditions: Hepatitis B

Interventions: Drug: Peginterferon-alfa 2a and tenofovir
Drug: Tenofovir

First Posted Date: 2011-06-08

Last Posted Date: 2023-04-28

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 201

Registration Number: NCT01369212

Locations: 🇨🇦
University of Toronto-Toronto Western Hospital, Toronto, Ontario, Canada
🇺🇸
University of California Los Angeles, Los Angeles, California, United States
🇺🇸
University of Texas Southwestern, Dallas, Texas, United States

and more 18 locations

The Safety, Pharmacokinetic Profile and Efficacy of Raltegravir in HIV-infected Patients at Least 60 Years of Age

Phase 4

Completed

Conditions: HIV

Interventions: Drug: Raltegravir
Drug: Tenofovir
Drug: Emtricitabine

First Posted Date: 2011-04-14

Last Posted Date: 2019-11-20

Lead Sponsor: Imperial College London

Target Recruit Count: 19

Registration Number: NCT01335620

Locations: 🇬🇧
Chelsea & Westminster Hospital NHS Trust, London, United Kingdom
🇬🇧
Imperial College Healthcare NHS Trust, London, United Kingdom

Comparative Safety Study of Two Vaginal Applicators With Tenofovir

Not Applicable

Completed

Conditions: Microbicide Applicator

Interventions: Drug: Tenofovir

First Posted Date: 2011-01-26

Last Posted Date: 2012-07-16

Lead Sponsor: PATH

Target Recruit Count: 25

Registration Number: NCT01283555

Locations: 🇩🇴
Clinica Profamilia, Santo Domingo, Dominican Republic

Randomized Controlled Study of Tenofovir Plus Telbivudine Versus Monotherapy With Either Drug in HBeAg Negative Chronic Hepatitis B Patients

Not Applicable

Withdrawn

Conditions: Chronic Hepatitis B

Interventions: Drug: Tenofovir plus Telbivudine
Drug: Tenofovir
Drug: Telbivudine

First Posted Date: 2010-12-15

Last Posted Date: 2015-06-16

Lead Sponsor: Institute of Liver and Biliary Sciences, India

Registration Number: NCT01260610

Locations: 🇮🇳
Institute of Liver & Biliary Sciences, New Delhi, India

Third Line Highly Active Antiretroviral Therapy (HAART) in HIV-infected Children

Completed

Conditions: This Study is Designed to Collect Treatment Data of Thai Children on Third Line ARV Therapy

Interventions: Drug: Tenofovir

First Posted Date: 2010-10-21

Last Posted Date: 2020-07-17

Lead Sponsor: The HIV Netherlands Australia Thailand Research Collaboration

Target Recruit Count: 56

Registration Number: NCT01225406

Locations: 🇹🇭
Chulalongkorn University, Bangkok, Thailand
🇹🇭
HIV-NAT, Bangkok, Thailand
🇹🇭
Siriraj Hospital, Mahidol University, Bangkok, Thailand

and more 6 locations

A Study of Pegasys (Peginterferon Alfa 2a) Alone or in Combination With Tenofovir in Patients With Chronic Hepatitis D.

Phase 3

Completed

Conditions: Hepatitis D, Chronic

Interventions: Drug: peginterferon alfa-2a [Pegasys]
Drug: placebo
Drug: tenofovir

First Posted Date: 2010-03-17

Last Posted Date: 2019-01-14

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 50

Registration Number: NCT01088659

Locations: 🇹🇷
Dokuz Eylul University Medical Faculty; Infection, Izmir, Turkey
🇹🇷
Istanbul Uni Cerrahpasa Medical Faculty; Gastroenterolgy, Istanbul, Turkey
🇹🇷
Ankara University Medical Facility; Hepatology Department, Ankara, Turkey

and more 3 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy